Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

(2012) Rosa Lapalombella et al.   CANCER CELL

XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells

(2012) S Rafiq et al.   LEUKEMIA

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

(2011) K.-H. Heider et al.   BLOOD

Modulation of antibody effector function

(2011) John R. Desjarlais et al.   EXPERIMENTAL CELL RESEARCH

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL

(2010) B. A. Nijmeijer et al.   BLOOD

B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody

(2010) R. Herbst et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

(2010) M Le Garff-Tavernier et al.   LEUKEMIA

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

(2010) Pier Paolo Piccaluga et al.   LEUKEMIA & LYMPHOMA

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

(2009) Shigeru Iida et al.   BMC CANCER

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis

(2009) S Q Ashraf et al.   BRITISH JOURNAL OF CANCER

Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia

(2009) Deborah A. Thomas et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma

(2009) J A Woyach et al.   LEUKEMIA

Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia

(2009) James Weitzman et al.   LEUKEMIA & LYMPHOMA

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases

(2008) P Chevallier et al.   LEUKEMIA

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS